CREDIT SUISSE NEW ISSUE: 4 American Call Warrants on Novartis Dienstag, 17. Mai 2022 - 11:23
Dear Investor
Please find hereafter the details for these new issues:
Ticker | Valor | ISIN | Underlying | Spot | Strike | Ratio | Maturity | Type | Issue price | Impl. Vola | PDF File |
MNOVCS | 11 620 2999 | CH 116 202 999 0 | Novartis AG | CHF 88.00 | CHF 96.00 | 15:1 | 16.09.2022 | Call | CHF 0.09 | 17.51% | |
NNOVCS | 11 620 3000 | CH 116 203 000 6 | Novartis AG | CHF 88.00 | CHF 100.00 | 15:1 | 16.09.2022 | Call | CHF 0.05 | 17.88% | |
ONOVCS | 11 620 3001 | CH 116 203 001 4 | Novartis AG | CHF 88.00 | CHF 96.00 | 15:1 | 16.12.2022 | Call | CHF 0.16 | 17.50% | |
PNOVCS | 11 620 3002 | CH 116 203 002 2 | Novartis AG | CHF 88.00 | CHF 100.00 | 15:1 | 16.12.2022 | Call | CHF 0.10 | 17.44% |
Please visit our website http://www.credit-suisse.com/derivatives to see the complete list of our products.
The warrants will be placed directly in the secondary market. Please call 044/335 76 00.
Kind regards
CREDIT SUISSE AG
Investment Banking
Equity Derivatives & Structured Products
Uetlibergstrasse 231
8070 Zürich, Switzerland
Tel: +41 44 - 335 76 00
Fax: +41 44 - 333 78 08
www.credit-suisse.com
This message may contain confidential, proprietary or legally privileged information and is intended only for the use of the addressee named above. No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient of this message you are hereby notified that you must not use, disseminate, copy it in any form or take any action in reliance on it. If you have received this message in error please delete it and any copies of it and notify the sender immediately. Credit Suisse Group and its subsidiaries reserve the right to intercept and monitor any e-mail communication through its networks if legally allowed.
===================================================================================
This message may contain confidential, proprietary or legally privileged information
and is intended only for the use of the addressee named above. No confidentiality or
privilege is waived or lost by any mistransmission. If you are not the intended
recipient of this message you are hereby notified that you must not use, disseminate,
copy it in any form or take any action in reliance on it. If you have received this
message in error please delete it and any copies of it and notify the sender immediately.
Credit Suisse Group AG and its subsidiaries reserve the right to retain, intercept
and monitor any e-mail communication through its networks if legally allowed. For
further information, please refer to the following link:
https://www.credit-suisse.com/sites/disclaimers/disclaimers-global/en/about-us/important-legal-information-csag.html
===================================================================================
==============================================================================
Where required by law, and except for FX instruments, pre-trade mid-market mark
is the arithmetic mean of bid and offer prices unless otherwise stated; other
regulatory disclosures are at https://plus.credit-suisse.com
==============================================================================